	US 12,433,886 B2
	Composition and method for reducing neutropenia
Lan Huang, New York, NY (US); George Kenneth Lloyd, New York, NY (US); and Ramon Mohanlal, New York, NY (US)
Assigned to BeyondSpring Pharmaceuticals, Inc., New York, NY (US)
Filed by BeyondSpring Pharmaceuticals, Inc., New York, NY (US)
Filed on Jan. 21, 2022, as Appl. No. 17/581,174.
Application 17/581,174 is a continuation of application No. 16/307,440, granted, now 11,229,642, previously published as PCT/US2017/035991, filed on Jun. 5, 2017.
Claims priority of provisional application 62/454,628, filed on Feb. 3, 2017.
Claims priority of provisional application 62/346,426, filed on Jun. 6, 2016.
Prior Publication US 2022/0143013 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 31/337 (2006.01); A61K 31/351 (2006.01); A61K 31/4745 (2006.01); A61K 31/664 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01); A61P 39/00 (2006.01)

CPC A61K 31/496 (2013.01) [A61K 31/337 (2013.01); A61K 31/351 (2013.01); A61K 31/4745 (2013.01); A61K 31/664 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); A61P 39/00 (2018.01)]

19 Claims

1. A method of reducing neutropenia in a subject, the method comprising:

administering about 10 mg/m²to about 50 mg/m²of plinabulin or a pharmaceutically salt thereof to the subject,

wherein the neutropenia is induced by administration of a first chemotherapeutic composition,

wherein the first chemotherapeutic composition comprises one or more agents selected from the group consisting of cyclophosphamide, ifosamide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, topotecan, doxorubicin, epirubicin, daunorubicin, valrubicin, and pharmaceutically acceptable salts thereof,

wherein the method does not comprise administering a taxane to the subject;

wherein the plinabulin is administered in the range of about 1 minute to about 24 hours after administration of the first chemotherapeutic composition.